Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes

Diabetes mellitus (DM) and hyperglycemia negatively affect the outcome and pathophysiology of acute ischemic stroke. The associations between DM and early neurological deterioration (END) [1, 2], more comorbidities [3], severe handicap and disability [4, 5], and increased mortality [3], have been repeatedly reported in both case-control [6] and cohort studies [7]. When the effects of hyperglycemia are included, these patients also present with more severe lesion size [8], more symptomatic intracranial hemorrhages [9, 10], edema [11], and mortality [12]. Although END is more frequently encountered in diabetic patients, the specific mechanisms underlying how DM promotes END are among the least clear. In clinical practice, being able to anticipate END would allow for more timely intervention; thus, gaining further insight into the mechanisms of END specific to patients with DM would improve the ability to identify and intervene in END in a population seemingly more susceptible to it. One possible mechanism linking DM with adverse outcomes of stroke involves fibrinogen, a prothrombotic protein, and acute phase reactant that is consistently elevated in patients with diabetes [13, 14]. In fact, a large body of evidence identifies fibrinogen as a mediator in the development of coronary artery thrombi and future cardiac events [15, 16]. However, the association of hyperfibrinogenemia and END in acute ischemic stroke has not yet been demonstrated. In this study, we evaluated whether elevated fibrinogen levels in patients with diabetes and acute ischemic stroke are associated with END in a large, single-center population.

In the non-DM population (END = 399, Non-END = 2055), age (65.3 ± 13.2 vs. 62.7 ± 14.3, p < 0.001), initial NIHSS (8.4 ± 6.8 vs. 5.6 ± 6.3, p < 0.001), and fasting glucose levels (125.6 ± 30.9 vs. 122.1 ± 29.7 mg/dL, p = 0.036) were significantly higher in the END group, as were differences in TOAST classification (p < 0.001) (Additional file 2: Table S1). Propensity score matching was performed for age, sex, initial NIHSS, and TOAST classification, with a relative multivariate imbalance measure L1 of 0.581 before matching, and 0.525 after matching. No covariate exhibited a large imbalance. After matching, TOAST classification (p = 0.003), elevated total cholesterol (179.5 ± 41.3 vs. 173.6 ± 38.4 mg/dL, p = 0.015), and elevated low density lipoprotein (108.2 ± 37.4 vs. 102.8 ± 34.3 mg/dL, p = 0.015) were significantly associated with END (Additional file 2: Table S1). In further regression analysis in the matched population, including age, male sex, presence of hypertension, initial NIHSS, TOAST classification, and total cholesterol levels as covariables, fibrinogen did not prove to be associated with END (p = 0.393) (Additional file 2: Table S2).

The results of this study suggest that hyperfibrinogenemia in patients with acute stroke and DM is associated with END, using both propensity score matching and multiple logistic regression analysis. Whereas the influence of hyperfibrinogenemia on END was consistently seen in the DM subgroup, it disappeared in the non-DM subgroup.

Hyperfibrinogenemia itself may directly induce a higher frequency of END in diabetic individuals through activation of the coagulation cascade. Fibrinogen forms fibrin clots as part of the final common stages of both the extrinsic and intrinsic pathways of the coagulation cascade [19]. Atherogenesis and the growth of atheromatous lesions are also initiated in part by fibrin deposition [20, 21]. Fibrinogen also facilitates platelet aggregation by binding to the glycoprotein IIb/IIIa receptor, increasing its reactivity [22].

Hyperfibrinogenemia may also indirectly reflect a prothrombotic condition induced by hyperinsulinemia and prolonged glycation. Levels of fibrinogen in diabetic patients correlate with insulin resistance and metabolic syndrome [13]. Prolonged glycation also induces a prothrombotic condition. Studies on fibrin clot structure under diabetic conditions have shown fibrinogen to be glycated in vivo [23], causing a change in the fibrin clot structure that reduces permeability [24], decreases fibrinolysis [25], and decreases α-chain crosslinking [26]. Thus, the effects of insulin resistance and prolonged glycation increase the risk of thrombosis, which underpins the development of vascular disease [27]. These studies lead us to assume that fibrinogen levels may represent a marker of platelet aggregation or progression to a prothrombotic phenotype in patients with diabetes [27].

This is the first study to link diabetic hyperfibrinogenemia to a higher frequency of END after ischemic stroke. Epidemiological studies have established that elevated fibrinogen levels are strongly and independently correlated with the risks of coronary arterial disease (CAD), stroke, and peripheral arterial disease [16, 28–31]. In stroke, carotid artery stenosis is significantly associated with elevated fibrinogen levels [32], and placebo data analysis in the Stroke Treatment with Ancrod Trial (STAT) and European Stroke Treatment with Ancrod Trial (ESTAT) has shown that plasma fibrinogen levels at stroke onset are independently associated with a poor functional outcome [33]. However, it has not been reported that hyperfibrinogenemia in patients with diabetes is associated with END in the acute stroke period.

It is conceivable that stronger antiplatelet treatments might be needed for patients with diabetes and hyperfibrinogenemia following acute ischemic stroke. Of note, elevated fibrinogen levels in our group of patients with diabetes may be linked to antiplatelet resistance, which may in turn result in END. Previous large scale trials, such as the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial [34], and the Prevention of Progression of Arterial Disease and Diabetes (POPAPAD) trial [35], have shown low efficacy of aspirin monotherapy for prevention of cardiovascular events in patients with diabetes. In addition, recent data show that responses to clopidogrel in patients with diabetes are suboptimal [36]. Such data suggest that diabetes is associated with considerable resistance to aspirin and clopidogrel therapy, and such insufficient antiplatelet responses could be an underlying causal factor for the frequent END observed in this population. In accordance with the elevated fibrinogen levels in our data, a recent study evaluating platelet aggregation characteristics in acute coronary syndrome found antiplatelet drug resistance to be significantly associated with metabolic syndrome, and fibrinogen levels and high sensitivity-CRP were higher in this population [37]. Serum fibrinogen levels appeared to be strongly associated with drug resistance [37]. In this case, elevated fibrinogen levels may call for more radical choices for antiplatelet therapy in such a population.

Apart from the antiplatelet issue, the idea that reduced fibrin, which is formed by fibrinogen in blood, may reduce blood viscosity, improve blood flow, and help remove the blood clot blocking the artery and re-establish blood flow has inspired clinical trials testing the therapeutic effects of the fibrin-depleting agents ancrod and defibrase [38]. In eight trials involving 5701 patients, fibrin-depleting agents marginally reduced the proportion of patients who were dead or disabled at the end of follow-up, and there were fewer stroke recurrences in the treatment group than in the control group. However, symptomatic intracranial hemorrhage was about twice as common in the treatment group compared with the control group [38]. The use of fibrin-depleting agents to reduce blood viscosity in patients with DM and elevated fibrinogen at risk for END holds similar problems. Plasma fibrinogen levels are associated with silent cerebrovascular lesions [39], and although this relationship may be evidence that increased viscosity by fibrinogen is a risk factor for stroke, deep white matter hyperintensities, on the other hand, are a known risk factor for intracerebral hemorrhage [40]. Accordingly, the use of fibrin-depleting agents in patients with DM may confer a higher risk of hemorrhagic complications. Thus, while the selective use of fibrin-depleting agents in patients with DM and END may be considered, further clinical studies to address the risks are needed prior to making such treatment a recommendation.

We acknowledge that our study has limitations. First, due to the retrospective nature of the study, there may be selection bias. We tried to minimize this issue by maximizing the number of patients included in the study and including adequate propensity score matching. Second, our somewhat long temporal definition of END (<7 days) incorporates a range of heterogeneous underlying mechanisms, and different definitions are used in other reports. Due to the retrospective nature and large number of enrolled patients in the study, the heterogeneity of END could not be addressed in this study. Third, because of the focus on lab data in this study, medication factors and imaging variables such as intracranial occlusion, stenosis, or diffusion weighted image volume were not included for analysis. However, variables that may have similar implications such as TOAST classification, and NIHSS scores were included, and the large patient numbers included may supplement such limitations. We hope to address these issues in later prospective studies.

In conclusion, hyperfibrinogenemia at admission in patients with acute ischemic stroke and DM is independently associated with END. This finding suggests that an elevated fibrinogen level is a marker of a prothrombotic or antiplatelet-resistant condition related to DM that could affect the patient’s prognosis. On the other hand, these results also reveal a category of patients wherein fibrin-depleting therapy could be significantly more effective.